jessie1 - where to begin. firstly, i was not rubbishing MLA. MLA...

jessie1 - where to begin. firstly, i was not rubbishing MLA. MLA have secured ALT 1 domestic hospital and are likely to secure another in the ST, for which all benefit.

I was pointing out your misguided view on the current arrangement and yet you still have the facts incorrect.

"ALT needs MLA in order to be successful". This is 100% untrue. You are inferring MLA are the only ones who can secure ALT licensing deals and that should they not, there is no other distributor who will and ALT will fail. This couchtrader is hogwash.

"Raise like the $2m+ it just needed to raise last month in order to stay afloat". Companies that are in the final stages of product development and rollout rely on external capital. Familiarise yourself with the product development cycle and associated costs for bio's and pharma's. They burn $millions through clinical trials, FDA and rollouts before they are revenue earning. This is common practice, whereas you are making out like it isn't the norm.

You might notice the directors invested over $1.2 million in the rights issue also. I'll let you work that out.

"Did you say "state the facts"? Then you need to practice what you preach". If you reread the past announcements, you will find I am indeed correct. MLA only have exclusivity in Australian, New Zealand and UK markets. The "view" to expand into the major market is nothing more than a view. You are assuming MLA have exclusivity worldwide due to some loose terminology in an announcement. $88million domestic for MLA (+UK), compared to $3billion worldwide where ALT can deal.

My point here is that if MLA had exclusivity worldwide, they would be a fair bet. However, there is a real possibility that they will secure the domestic market and sure enough an international will want to deal. MLA has no right to a slice of this pie. If ALT decide to partner with a much bigger distributor for American and European markets, MLA's upside is limited to the $88million domestic market.

If you look at the shareprice, mr market agrees with me. I am not denying there will be significant upside for MLA to secure the domestic market here, but the real rerating is those major international markets which MLA are not exclusively and unconditionally entitled to, so indeed your upside is limited.

Again, I wasn't rubbishing MLA, but please don't make out like MLA is ALT's savior and ALT is incapable.

woodduck